SEC Comment Letter for Corbus Pharmaceuticals Holdings, Inc. (CRBP) (CIK 0001595097) (CRBP) — Jun 7, 2023
Corbus Pharmaceuticals Holdings, Inc. (CRBP) (CIK 0001595097)
Date: June 7, 2023 · CIK: 0001595097 · Accession: 0000000000-23-006053
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-272314
Letter
United States securities and exchange commission logo June 7, 2023 Sean Moran Chief Financial Officer Corbus Pharmaceuticals Holdings, Inc. 500 River Ridge Drive Norwood, MA 02062 Re:Corbus Pharmaceuticals Holdings, Inc. Registration Statement on Form S-3 Filed June 1, 2023 File No. 333-272314 Dear Sean Moran: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Michael Lerner
Show Raw Text
United States securities and exchange commission logo
June 7, 2023
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals Holdings, Inc.
500 River Ridge Drive
Norwood, MA 02062
Re:Corbus Pharmaceuticals Holdings, Inc.
Registration Statement on Form S-3
Filed June 1, 2023
File No. 333-272314
Dear Sean Moran:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Michael Lerner